Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Abbott Laboratories    ABT

ABBOTT LABORATORIES

(ABT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Abbott Laboratories : 4Q Profit, Sales Rise

share with twitter share with LinkedIn share with facebook
share via e-mail
01/22/2020 | 08:05am EDT

By Dave Sebastian

Abbott Laboratories (ABT) said its profit and sales rose in the fourth quarter.

The Abbott Park, Ill.-based maker of health-care products reported $8.31 billion in sales for the quarter, compared with $7.77 billion in the prior year. Analysts polled by FactSet were looking for $8.27 billion.

The company said sales for its medical devices rose 11% on an organic basis, led by double-digit organic sales growth in heart failure, electrophysiology, structural heart and diabetes care.

Sales in the company's established pharmaceuticals unit rose 10% on an organic basis from a year earlier. Its diagnostics segment sales rose 6.4% on an organic basis, while organic sales for its nutrition segment rose 5.8%.

Net income rose to $1.05 billion from $654 million in the year-ago period. Adjusted earnings were 95 cents a share, meeting analysts' expectations.

Write to Dave Sebastian at dave.sebastian@wsj.com

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ABBOTT LABORATORIES
03/27ABBOTT : Launches Molecular Point-of-Care Test to Detect Novel Coronavirus in as..
PR
03/27Transmission of Annual Report for the Year Ended December 31, 2019 of Abbott ..
AQ
03/19ABBOTT : Hosts Conference Call for First-Quarter Earnings
PR
03/18ABBOTT LABORATORIES : Shipping 150,000 Coronavirus Tests
DJ
03/18ABBOTT : Receives FDA Emergency Use Authorization and Launches Test to Detect No..
PR
03/18Annual general meeting of Abbott Laboratories Limited to be held on April 20,..
AQ
03/06ABBOTT LABORATORIES : Aims to optimize tavi implants with european approval of f..
AQ
03/05ABBOTT : Aims to Optimize TAVI Implants with European Approval of FlexNav™..
PR
03/03The Race to Develop Tests to Spot Coronavirus-Linked Illness -- Update
DJ
03/03Hospitals, Companies Race to Develop Tests to Spot Coronavirus-Linked Illness
DJ
More news
Financials (USD)
Sales 2020 33 895 M
EBIT 2020 7 577 M
Net income 2020 4 460 M
Debt 2020 10 625 M
Yield 2020 1,91%
P/E ratio 2020 29,5x
P/E ratio 2021 24,1x
EV / Sales2020 4,19x
EV / Sales2021 3,78x
Capitalization 131 B
Chart ABBOTT LABORATORIES
Duration : Period :
Abbott Laboratories Technical Analysis Chart | ABT | US0028241000 | MarketScreener
Technical analysis trends ABBOTT LABORATORIES
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 97,00  $
Last Close Price 74,56  $
Spread / Highest target 47,5%
Spread / Average Target 30,1%
Spread / Lowest Target 4,61%
EPS Revisions
Managers
NameTitle
Miles D. White Chairman & Chief Executive Officer
Robert B. Ford President, Chief Operating Officer & Director
Robert E. Funck Chief Financial Officer & Executive Vice President
Roxanne Schuh Austin Independent Director
Samuel C. Scott Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ABBOTT LABORATORIES-14.16%131 482
MASIMO CORPORATION13.27%9 631
NOVOCURE LIMITED-22.27%6 526
ASAHI INTECC CO., LTD.-8.89%6 501
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD.0.52%5 383
GETINGE5.43%4 916